title: [Clinical application of FdUrd to meningeal dissemination of malignant tumors].
abstract: A clinical trial of intrathecal chemotherapy with FdUrd was performed in sixteen patients with meningeal dissemination of malignant tumors. Twelve of the sixteen patients responded to intrathecal FdUrd chemotherapy (1-5 micrograms/dose) through an Ommaya reservoir placed in the lateral ventricle: complete response, 2; partial response, 10; progressive disease, 4. Only slight nausea was observed in two patients and dull headache in one patient. No other systemic side effects such as myelosuppression or liver dysfunction were observed in any patients. Moreover, no delayed side effects such as marked brain atrophy or leukoencephalopathy developed during the course of this intrathecal chemotherapy despite over thirty consecutive intrathecal administrations. In conclusion, intrathecal FdUrd proved to be safe and effective for the treatment of meningeal dissemination of malignant tumors.
authors.affiliation: Department of Neurosurgery, Osaka Medical Center for Cancer and Cardiovascular Diseases (OMCC), Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: N
authors.initials: N
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Iwatsuki
authors.forename: T
authors.initials: T
authors.lastname: Tsuzuki
authors.forename: A
authors.initials: A
authors.lastname: Hirayama
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Ikenaka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy / Q000556:secondary; D006801:Humans; D015918:Infusion Pumps, Implantable; D007278:Injections, Spinal; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; C051858:3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine